Publications by authors named "Akiko Morinaga"

Article Synopsis
  • Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease, and recent research reveals the Src/c-Abl inhibitor, bosutinib, as a promising candidate for treatment after a phase 1 study showed it to be safe for ALS patients.
  • The ongoing phase 2 study aims to assess bosutinib's efficacy and long-term safety over a 24-week treatment period, with 25 ALS patients participating and receiving either 200 mg or 300 mg doses.
  • The study has ethical approval from multiple universities and plans to share its findings in peer-reviewed journals and scientific conferences.
View Article and Find Full Text PDF

In this study, we aimed to separately evaluate the relationship between waist circumference and the incidence of hyperuricemia in men and women in the general Japanese population. We performed a population-based longitudinal study using data from the annual health examination of residents of Iki City, Japan. A total of 5567 participants without hyperuricemia at baseline were included in the analysis.

View Article and Find Full Text PDF

Objective: We aimed to clarify the relationship between serum alanine transaminase (ALT) levels and incidence of new-onset diabetes in a Japanese general population.

Setting: Population-based retrospective cohort study using annual health check-up data for residents of Iki City, Nagasaki Prefecture, Japan.

Participants: A total of 5330 Japanese individuals (≥30 years old) without diabetes at baseline were analysed.

View Article and Find Full Text PDF
Article Synopsis
  • ALS is a serious neurodegenerative disease that urgently requires new treatment options, prompting the investigation of the Src/c-Abl inhibitor bosutinib, originally used for chronic myelogenous leukemia (CML), as a potential therapy for ALS.
  • The study was a phase 1 trial conducted in Japan to assess the safety and tolerability of bosutinib in ALS patients, with participants receiving escalating doses, starting from 100 mg to 400 mg, based on the occurrence of dose-limiting toxicities (DLTs).
  • Results showed that the drug was generally well-tolerated at doses up to 300 mg, with common side effects being gastrointestinal issues, liver function changes, and rashes; however, DLTs occurred at
View Article and Find Full Text PDF

The aim of this study was to investigate the association between pulse pressure (PP) and chronic kidney disease (CKD) progression among the general population in Japan. We conducted a population-based cohort study of the residents of Iki Island, Nagasaki, Japan, from 2008 to 2018. We identified 1042 participants who had CKD (estimated glomerular filtration rate(eGFR) < 60 mL/min/1.

View Article and Find Full Text PDF

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive and severe neurodegenerative disease caused by motor neuron death. There have as yet been no fundamental curative medicines, and the development of a medicine for ALS is urgently required. Induced pluripotent stem cell (iPSC)-based drug repurposing identified an Src/c-Abl inhibitor, bosutinib, as a candidate molecular targeted therapy for ALS.

View Article and Find Full Text PDF

Background: Additive antitumor effects could be achieved by combination of immunotherapy and cytotoxic agents with no or minimum suppression.

Methods: Thirteen patients positive for human leukocyte antigen (HLA)-A24 or -A2 with metastatic hormone refractory prostate cancer (HRPC) who had failed to respond to the prior-peptide vaccination were entered in the combined peptide vaccination and estramustine phosphate. Conducted immune monitoring on those 13 patients were mainly peptide-specific cytotoxic T lymphocyte (CTL) precursor analysis by IFN-gamma productions and peptide-reactive IgG by an enzyme-linked immunosorbent assay (ELISA).

View Article and Find Full Text PDF

Identification of antigenic peptides expressed on cancer cells enables us to treat cancer patients with peptide-based immunotherapy. Although optimal protocols for peptide-based vaccines have not yet been elucidated, boosting the immune system could be a better approach than priming the immune system to elicit prompt and potent peptide-specific T-cell responses in cancer patients. With this possibility in mind, the authors undertook a clinical trial in which cancer patients were vaccinated with peptides (maximum 4) after confirmation of pre-existing peptide-specific cytotoxic T-lymphocyte (CTL) precursors in the periphery.

View Article and Find Full Text PDF